{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T22:12:36Z","timestamp":1772662356080,"version":"3.50.1"},"reference-count":47,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,10,18]],"date-time":"2014-10-18T00:00:00Z","timestamp":1413590400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite a wide spectrum of treatment options, mantle cell lymphoma (<jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>) remains a challenging hematologic malignancy to manage. Advances in front\u2010line therapy, including the monoclonal antibody rituximab and increasing use of cytarabine, have improved remission rates. Autologous hematopoietic cell transplantation (<jats:styled-content style=\"fixed-case\">HCT<\/jats:styled-content>) can effectively consolidate remission of <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>, leading to encouraging survival beyond 5\u00a0yr. However, nearly all patients with <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content> will relapse and require salvage therapy. Novel agents such as ibrutinib, bortezomib, and lenalidomide have dramatically expanded the options for treating relapsed <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>. In this review, we summarize the clinical evidence supporting the use of allogeneic donor <jats:styled-content style=\"fixed-case\">HCT<\/jats:styled-content> in <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content> and make recommendations on indications for its use. Data suggest that allogeneic donor <jats:styled-content style=\"fixed-case\">HCT<\/jats:styled-content> is the only curative therapy for patients with poor prognosis or aggressive <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>. Patient selection, timing, and optimal use remain a matter of scientific debate and given the rapidly changing therapeutic landscape of <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>, the outcomes of allogeneic <jats:styled-content style=\"fixed-case\">HCT<\/jats:styled-content> should be interpreted in the context of novel therapeutics.<\/jats:p>","DOI":"10.1111\/ejh.12442","type":"journal-article","created":{"date-parts":[[2014,8,23]],"date-time":"2014-08-23T14:17:26Z","timestamp":1408803446000},"page":"290-297","source":"Crossref","is-referenced-by-count":12,"title":["Role of allogeneic stem cell transplantation in mantle cell lymphoma"],"prefix":"10.1111","volume":"94","author":[{"given":"Jonathon B.","family":"Cohen","sequence":"first","affiliation":[{"name":"Division of Stem Cell and Immune Therapy Department of Hematology and Medical Oncology Winship Cancer Institute of Emory University Atlanta  GA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda J.","family":"Burns","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Program Department of Medicine University of Minnesota Minneapolis MN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika","family":"Bachanova","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Program Department of Medicine University of Minnesota Minneapolis MN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,10,18]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095331"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.2466"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802419640"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4079"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22123"},{"key":"e_1_2_7_7_1","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1182\/blood.V120.21.2691.2691","article-title":"Complex Karyotype (CK) Is Associated with a Shortened Progression\u2010Free Survival (PFS) in Patients (pts) with Newly Diagnosed Mantle Cell Lymphoma (MCL)","volume":"120","author":"Cohen JB","year":"2012","journal-title":"Blood"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-391474"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3419"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12854"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.46"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.10.007"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3883"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11838"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.201"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.2554"},{"key":"e_1_2_7_17_1","first-page":"96","article-title":"Bortezomib maintenance (BM) versus consolidation (BC) following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell lymphoma (MCL): CALGB 50403","volume":"31","author":"Kaplan LD","year":"2013","journal-title":"Hematol Oncol"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-370320"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200920"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08820.x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu097"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1816.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701044"},{"key":"e_1_2_7_25_1","first-page":"656a","article-title":"Allogeneic stem cell transplantation for mantle cell lymphoma (MCL): Evidence of graft\u2010versus\u2010lymphoma effect (GVL)","volume":"92","author":"Khouri I","year":"1998","journal-title":"Blood"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.01.008"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.02.014"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2006.08.035"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.501"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-11-0107"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds054"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.2454"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.01.009"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.01.010"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.04.006"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2275"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2087-z"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620710396752"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-324392"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705919"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270538"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06908.x"},{"key":"e_1_2_7_43_1","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1182\/blood.V120.21.3092.3092","article-title":"Autologous and Allogeneic Donor Transplantation for Mantle Cell Lymphoma in Rituximab Era: Impact of Pre\u2010Transplant Burden On Survival","volume":"120","author":"Magnusson EA","year":"2012","journal-title":"Blood"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.02.009"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.05.006"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9665"},{"key":"e_1_2_7_48_1","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood.V120.21.905.905","article-title":"Phase II Multicenter Study of Single\u2010Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL\u2010001 \u201cEMERGE\u201d Study","volume":"120","author":"Goy A","year":"2012","journal-title":"Blood"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12442","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.12442","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T07:37:27Z","timestamp":1696318647000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.12442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,18]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1111\/ejh.12442"],"URL":"https:\/\/doi.org\/10.1111\/ejh.12442","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,18]]}}}